Strategy

Driving forces
The major driving forces for pharmaceutical, biotech and diagnostics companies can be described as "faster", "smaller" and "lower cost". Microfluidics is a technology that can respond to all of these driving forces.

Gyros proprietary microfluidic technology allows integration and miniaturization of laboratory processes into a CD format (smaller). This not only simplifes the analysis procedure but also lays a new foundation for cost-effective analysis to meet the search for reliable information in ever increasing sample numbers (lower cost). The CD technology enables pharmaceutical, biotech and clinical diagnostics laboratories to improve performance, increase sample throughput (faster) and reduce consumption of samples and reagents for protein based applications.

Gyros will continue to grow through launching new applications that focus on automating and integrating lab processes to meet customer needs for faster / smaller / lower cost solutions.

Gyros and in vitro diagnostics for medical applications
Within the IVD market, Gyros focuses on immunoassays, clinical chemistry and point-of-care testing. Gyros addresses these segments through collaborations with established IVD instrument supply companies to jointly develop instruments and custom made CDs based on Gyros CD technology.

Today a full service clinical laboratory needs different instruments for different applications e.g. one instrument for immunoassays and another instrument for clinical chemistry etc. Gyros CD technology can provide a unique benefit to these laboratories by only requiring a single instrument, which can be used with different CD microlaboratories to run many different clinical applications.

Gyros in the protein analysis market
Gyros focuses on protein quantification applications used in several phases of the R&D drug development chain where the inherent advantages of Gyros CD technology provide benefits over current, established methods.

Gyrolab Bioaffy^® uses the CD technology in the format of a flow-through immunoassay. CD microlaboratories are processed in a software controlled and fully automated instrument to give customers a fast, convenient and robust solution for the quantification of many different types of proteins, e.g. monoclonal antibodies for therapeutic use, cytokines and insulin.

An example of a targeted biopharmaceutical application is process optimization and quantification of monoclonal antibody drugs intended for therapeutic use. Here, current technologies (ELISA and HPLC) are hampered by long assay times or low analytical capacity and require a considerable amount of 'hands-on' time to adjust sample concentrations into the 'measurable' range. By miniaturizing the application into Gyros CD technology, assays in general gain a measuring range of more than 10⁴ and, when using very small sample volumes, i.e. subnanoliter volumes, > 100 data points are processed at very high concentrations in less than one hour.

The protein analysis market is addressed through the Company's marketing and sales organization.